Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
A study of Keytruda (pembrolizumab) in patients with a difficult-to-treat type of liver cancer suggests that the treatment may extend the ... Read more
A rare type of malignant melanoma is treatable with immunotherapies, according to a new study — overturning previous beliefs that the cancer, ... Read more
Adding Tecentriq (atezolizumab) to a treatment of Avastin (bevacizumab) and chemotherapy significantly prolonged the time to disease progression or death in ... Read more
In an unprecedented collaborative effort, Stand Up To Cancer (SU2C) has launched 10 clinical trials through its therapy development initiative SU2C ... Read more
Amgen’s virus therapy against metastatic malignant melanoma, Imlygic, appears to boost the effects of Yervoy (ipilimumab), according to the results of ... Read more
Researchers have developed guidelines for handling the potentially fatal side effects of CAR T-cell therapy, which along with its unprecedented efficacy ... Read more
Canadian patients with metastatic non-small cell lung cancer (NSCLC) can now receive Merck‘s Keytruda (pembrolizumab) as their first treatment following a recent approval ... Read more
The European Commission (EC) has granted Bavencio (avelumab) marketing approval as the first immunotherapy to treat the aggressive skin cancer metastatic Merkel ... Read more
